Starlix

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Type 2 DiabetesInsulin ResistanceInsulin Secretion

171 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

1

Starlix

Novartis

Approved

12

NOVOLIN R

Novo Nordisk

Preclinical

53

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

24

Aurlumyn

BBTG International Inc.

Preclinical

15

Nexium

DDexcel Pharma Technologies Ltd.

Preclinical

16

Inderal

WWyeth-Lederle Vaccines

Preclinical

17

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

18

SGLT-2 Inhibitor

SSheffield Teaching Hospitals NHS Foundation Trust

Preclinical

29

Routine Treatment

GSK

Preclinical

110

Sulfonylureas

Eli Lilly

Preclinical

1Show 27 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Type 2 Diabetic Patients3 trials

A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic Patients

Completed·Astellas·Phase 3·NCT01316107·122 enrolled

Nateglinide: a Double Blind Add-on Study With Pioglitazone for Type 2 Diabetic Patients

Completed·Astellas·Phase 2/3·NCT00189774

The Effects of Nateglinide and Acarbose on the Post-Prandial Glucose Control in Type 2 Diabetic Patients

Completed·IInje University·Phase 4·NCT00437918·85 enrolled

Labor2 trials

Bioequivalence Study of Nateglinide Tablets 120 mg of Dr. Reddy's Laboratories Limited Under Fed Condition

Completed·—·Phase 1·NCT01160029·58 enrolled

Bioequivalence Study of Nateglinide Tablets 120 mg of Dr. Reddy's Laboratories Limited Under Fasting Condition

Completed·—·Phase 1·NCT01159158·68 enrolled

Insulin resistance2 trials

Insulin Resistance and Vessel Function After Meals: Does Early Intervention Make a Difference?

Completed·AAtheline Major-Pedersen·Phase 4·NCT00259168·70 enrolled

Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes

Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 4·NCT00212290·140 enrolled

Type 2 Diabetes1 trial

Safety and Efficacy of Nateglinide in Patients With Type 2 Diabetes Already Taking Insulin Glargine, Metformin and/or Pioglitazone or Rosiglitazone

Completed·Novartis·Phase 4·NCT00402909·28 enrolled

Hemodynamic1 trial

A Pilot Study to Evaluate the Effects of Nateglinide vs. Glibenclamide on Renal Hemodynamics and Albumin Excretion

Completed·Novartis·Phase 4·NCT00238472·24 enrolled

5 more indications

Fasting Conditions1 trial

A Open-label, Single-dose, 2-Sequence, 2-Period, Crossover Study to Assess Safety and Pharmacokinetics of a Nateglinide/Metformin HCl Combined Tablet Compared With a Nateglinide 120 mg Tablet and Metformin HCl 500 mg Tablet Under Fasting Conditions in Healthy Male Subjects

Completed·IlDong Pharmaceutical Co Ltd·Phase 1·NCT02088918·40 enrolled

Insulin Secretion1 trial

Effects of Nateglinide on Postprandial Glucose Excursion by Restoring Early Phase Insulin Secretion

Completed·Novartis·Phase 4·NCT01030952·103 enrolled

Dyslipidemia1 trial

Effects of Nateglinide vs Acarbose on Postprandial Glucose Fluctuation, Dyslipidemia, and Inflammatory Factors

Completed·Novartis·Phase 4·NCT00928889·160 enrolled

Renal Transplant Recipients1 trial

Efficacy and Safety of Nateglinide Treatment in Renal Transplant Recipients

Completed·UUniversity of Oslo School of Pharmacy·Phase 4·NCT00319189·15 enrolled

Unspecified1 trial

Study of the Durability of Glycemic Control With Nateglinide

Completed·—·Phase 4·NCT00858013·88 enrolled

Regulatory

FDA Approval Timeline[4]

Details

Drug Info

Related News